A permanent treatment with stem-cell based therapy for treating diabetes is about to reach patients as Johnson & Johnson, an American pharmaceutical company and ViaCyte, Inc., a player in regenerative medicine has joined forces to expedite the process of development of a stem-cell based cure for type 1 diabetes.
